Close
Found 0 results for your search. Showing 0 to 0.
No results could be found for your search.
x Close Search
Close

Publications

Vaccine safety surveillance in pregnancy in low- and middle-income countries using GAIA case definitions: A feasibility assessment.
Stuurman, AL; Riera, M; Lamprianou, S; Perez-Vilar, S; Anderson, SA; MANGTANI, P; Devlieger, H; Verstraeten, T; Zuber, PL F; Guillard Maure, C;
2018
Vaccine, (2018).36 45 10.1016/j.vaccine.2018.09.033.
Antibody responses to Schistosoma mansoni schistosomula antigens.
EGESA, M; Lubyayi, L; Jones, FM; Van Diepen, A; Chalmers, IW; Tukahebwa, EM; Bagaya, BS; Hokke, CH; Hoffmann, KF; Dunne, DW; ELLIOTT, AM; Yazdanbakhsh, M; Wilson, S; COSE, S;
2018
Parasite immunology, (2018).40 12 10.1111/pim.12591.
Vaccine confidence and hesitancy in Brazil.
Brown, AL; Sperandio, M; Turssi, CP; Leite, RM A; Berton, VF; Succi, RM; LARSON, H; Napimoga, MH;
2018
Cadernos de saude publica, (2018).34 9 10.1590/0102-311X00011618.
Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A.
WAJJA, A; Namutebi, M; Apule, B; Oduru, G; Kiwanuka, S; Akello, M; Nassanga, B; Kabagenyi, J; Mpiima, J; Vermaak, S; Lawrie, A; Satti, I; Verweij, J; COSE, S; Levin, J; KALEEBU, P; Tukahebwa, E; McShane, H; ELLIOTT, AM;
2018
Wellcome open research, (2018).3, 10.12688/wellcomeopenres.14736.1.
Using vaccine Immunostimulation/Immunodynamic modelling methods to inform vaccine dose decision-making.
RHODES, SJ; Guedj, J; FLETCHER, HA; Lindenstrøm, T; Scriba, TJ; Evans, TG; KNIGHT, GM; WHITE, RG;
2018
NPJ Vaccines, (2018).3 1 10.1038/s41541-018-0075-3.
Vaccine safety surveillance in pregnancy in low- and middle-income countries using GAIA case definitions: A feasibility assessment.
Stuurman, AL; Riera, M; Lamprianou, S; Perez-Vilar, S; Anderson, SA; MANGTANI, P; Devlieger, H; Verstraeten, T; Zuber, PL F; Guillard Maure, C;
2018
Vaccine, (2018).36 45 10.1016/j.vaccine.2018.09.033.
HPV vaccine confidence and cases of mass psychogenic illness following immunization in Carmen de Bolivar, Colombia.
Simas, C; Munoz, N; Arregoces, L; LARSON, HJ;
2018
Human vaccines & immunotherapeutics, (2018).15 1 10.1080/21645515.2018.1511667.
Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine.
WILDER-SMITH, A; Hombach, J; Ferguson, N; Selgelid, M; O'Brien, K; Vannice, K; Barrett, A; Ferdinand, E; FLASCHE, S; Guzman, M; Novaes, HM; Ng, L-C; SMITH, PG; Tharmaphornpilas, P; Yoon, I-K; Cravioto, A; Farrar, J; Nolan, TM;
2018
The Lancet infectious diseases, (2018).19 1 10.1016/S1473-3099(18)30494-8.
Cost-benefit analysis of vaccination: a comparative analysis of eight approaches for valuing changes to mortality and morbidity risks.
Park, M; JIT, M; Wu, JT;
2018
BMC medicine, (2018).16 1 10.1186/s12916-018-1130-7.
Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A.
WAJJA, A; Namutebi, M; Apule, B; Oduru, G; Kiwanuka, S; Akello, M; Nassanga, B; Kabagenyi, J; Mpiima, J; Vermaak, S; Lawrie, A; Satti, I; Verweij, J; COSE, S; Levin, J; KALEEBU, P; Tukahebwa, E; McShane, H; ELLIOTT, AM;
2018
Wellcome open research, (2018).3, 10.12688/wellcomeopenres.14736.1.